ATE377606T1 - Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren - Google Patents

Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren

Info

Publication number
ATE377606T1
ATE377606T1 AT98930536T AT98930536T ATE377606T1 AT E377606 T1 ATE377606 T1 AT E377606T1 AT 98930536 T AT98930536 T AT 98930536T AT 98930536 T AT98930536 T AT 98930536T AT E377606 T1 ATE377606 T1 AT E377606T1
Authority
AT
Austria
Prior art keywords
receptors
protein coupled
coupled receptors
cyclic antagonists
protein
Prior art date
Application number
AT98930536T
Other languages
German (de)
English (en)
Inventor
David Fairlie
Stephen Taylor
Angela Finch
Allan Wong
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE377606T1 publication Critical patent/ATE377606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
AT98930536T 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren ATE377606T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist

Publications (1)

Publication Number Publication Date
ATE377606T1 true ATE377606T1 (de) 2007-11-15

Family

ID=3801840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930536T ATE377606T1 (de) 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren

Country Status (11)

Country Link
US (5) USRE41287E1 (https=)
EP (1) EP1017713B1 (https=)
JP (1) JP4686696B2 (https=)
AT (1) ATE377606T1 (https=)
AU (2) AUPO755097A0 (https=)
CY (1) CY1107133T1 (https=)
DE (1) DE69838678T2 (https=)
DK (1) DK1017713T3 (https=)
ES (1) ES2294816T3 (https=)
PT (1) PT1017713E (https=)
WO (1) WO1999000406A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
CA2418652C (en) 2000-08-10 2010-03-23 Mitsubishi Pharma Corporation Novel 3-substituted urea derivatives and medicinal use thereof
US7855297B2 (en) 2000-09-14 2010-12-21 Mitsubishi Tanabe Pharma Corporation Amide derivatives and medicinal use thereof
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
JP4290564B2 (ja) 2002-03-19 2009-07-08 チルドレンズ ホスピタル メディカル センター Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US7410945B2 (en) * 2002-10-16 2008-08-12 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
CA2579678A1 (en) * 2004-10-04 2006-04-13 Alchemia Limited Selective inhibitors
CN101107264A (zh) * 2005-01-17 2008-01-16 捷瑞尼股份公司 C5a受体拮抗剂
AU2006223108A1 (en) * 2005-03-11 2006-09-21 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
US20100000605A1 (en) * 2008-07-02 2010-01-07 Saint-Gobain Performance Plastics Chaineux Framed device, seal, and method for manufacturing same
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
AU2011207441A1 (en) * 2010-01-22 2012-08-09 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP2824111B1 (en) 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
AU2011276445A1 (en) 2010-06-29 2013-02-21 Board Of Regents Of The University Of Nebraska Analogs of C5a and methods of using same
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA2908552A1 (en) * 2013-04-02 2014-10-09 The Scripps Research Institute Uses of cyclic peptides for treating and preventing atherosclerosis
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US20190270778A1 (en) 2016-07-29 2019-09-05 Pfizer Inc. Cyclic Peptides As C5a Receptor Antagonists
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
EP3642230A1 (en) 2017-06-23 2020-04-29 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
EP4126222A1 (en) 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
NZ274917A (en) 1993-12-06 1998-03-25 Novartis Ag Peptide analogs of human c5a (from complement system), their production, coding sequences and diagnostic and therapeutic uses
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Also Published As

Publication number Publication date
DK1017713T3 (da) 2008-02-11
CY1107133T1 (el) 2012-10-24
US20090203760A1 (en) 2009-08-13
US20130005644A1 (en) 2013-01-03
AUPO755097A0 (en) 1997-07-17
DE69838678T2 (de) 2008-10-30
AU8092698A (en) 1999-01-19
DE69838678D1 (de) 2007-12-20
US6821950B1 (en) 2004-11-23
US20060160726A1 (en) 2006-07-20
EP1017713A1 (en) 2000-07-12
USRE41287E1 (en) 2010-04-27
JP2002508767A (ja) 2002-03-19
EP1017713A4 (en) 2002-07-24
HK1029595A1 (en) 2001-04-06
ES2294816T3 (es) 2008-04-01
EP1017713B1 (en) 2007-11-07
PT1017713E (pt) 2007-12-18
AU744991B2 (en) 2002-03-07
JP4686696B2 (ja) 2011-05-25
WO1999000406A1 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
DE69838678D1 (de) ZYKLISCHE ANTAGONISTEN DER C5a REZEPTOREN SOWIE DER G-PROTEIN GEKOPPELTEN REZEPTOREN
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
IS5543A (is) Nýr G próteintengdur viðtaki
EA200300663A1 (ru) Антагонисты cxcr3
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE440827T1 (de) Melanocortin-rezeptormodulatoren
PT934310E (pt) N-heterociclicos monociclicos substituidos por tioacido uteis como anti-coagulantes
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
YU34898A (sh) Antagonisti ccr-3 receptora
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
DE60038686D1 (de) Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
EA200200933A1 (ru) Антагонисты рецептора il-8
CY1107739T1 (el) Ανταγωνιστες υποδοχεων οπιοειδων σε διαδερματικα συστηματα με μπουπρενορφινη
ATE266722T1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
BR0011122A (pt) Antagonistas de receptor il-8
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
EP0862627A4 (en) RECEPTOR OF Y-Y5 NEUROPEPTID
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
ATE343634T1 (de) Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017713

Country of ref document: EP